P-glycoprotein Overexpression in Bone Marrow-derived Multipotent Stromal Cells Decreases the Risk of Steroid-induced Osteonecrosis in the Femoral Head
Overview
Molecular Biology
Affiliations
P-glycoprotein (P-gp) plays a role in steroid-induced osteonecrosis of the femoral head (ONFH), but the underlying mechanism remains unknown. We hypothesized that P-gp overexpression can prevent ONFH by regulating bone marrow-derived multipotent stromal cell (BMSC) adipogenesis and osteogenesis. BMSCs from Sprague-Dawley rats were transfected with green fluorescent protein (GFP) or the multidrug resistance gene 1 (MDR1) encoding GFP and P-gp. Dexamethasone was used to induce BMSC differentiation. Adipogenesis was determined by measuring peroxisome proliferator-activated receptor (PPAR-γ) expression and the triglyceride level. Osteogenesis was determined by measuring runt-related transcription factor 2 (Runx2) expression and alkaline phosphatase activity. For in vivo experiments, rats were injected with saline, BMSCs expressing GFP (GFP-BMSCs) or BMSCs expressing GFP-P-gp (MDR1-GFP-BMSCs). After dexamethasone induction, adipogenesis was determined by measuring PPAR-γ expression and fatty marrow, whereas osteogenesis was detected by measuring Runx2 expression, trabecular parameters and the mineral apposition rate, followed by evaluation of the incidence of ONFH. Overexpression of P-gp in BMSCs resulted in markedly decreased expression of adipogenic markers and increased expression of osteogenic markers. Compared with rats injected with saline, rats injected with GFP-BMSCs showed reduced ONFH, and the injected GFP-positive BMSCs attached to trabecular surfaces and exhibited an osteoblast-like morphology. Compared with the rats injected with BMSCs expressing GFP alone, rats injected with BMSCs overexpressing GFP and P-gp showed lower adipocytic variables, higher osteogenic variables and lower incidence of ONFH. Overexpression of P-gp inhibited BMSC adipogenesis and promoted osteogenesis, which reduced the incidence of steroid-induced ONFH.
Huang M, Liu H, Zhu L, Li X, Li J, Yang S J Cell Physiol. 2021; 236(9):6391-6406.
PMID: 33554336 PMC: 8222149. DOI: 10.1002/jcp.30314.
Stem cell therapy for osteonecrosis of femoral head: Opportunities and challenges.
Xu Y, Jiang Y, Xia C, Wang Y, Zhao Z, Li T Regen Ther. 2021; 15:295-304.
PMID: 33426232 PMC: 7770428. DOI: 10.1016/j.reth.2020.11.003.
The Protective Effect of Luteolin in Glucocorticoid-Induced Osteonecrosis of the Femoral Head.
Yan Z, Zhan J, Qi W, Lin J, Huang Y, Xue X Front Pharmacol. 2020; 11:1195.
PMID: 32903480 PMC: 7435053. DOI: 10.3389/fphar.2020.01195.
Kong L, Zuo R, Wang M, Wang W, Xu J, Chai Y Int J Biol Sci. 2020; 16(4):655-670.
PMID: 32025213 PMC: 6990928. DOI: 10.7150/ijbs.38713.
Multiscale Stem Cell Technologies for Osteonecrosis of the Femoral Head.
Wang Y, Ma X, Chai W, Tian J Stem Cells Int. 2019; 2019:8914569.
PMID: 30728843 PMC: 6341242. DOI: 10.1155/2019/8914569.